From today's Times:

Tiddler to watch

"ImmuPharma, steady at 46p, the biotech group which has a treatment of the disease Lupus in phase II trials, could benefit from the failure this week of trials of rival drug Rituxan. ImmuPharma's housebroker, Panmure Gordon, believes its client may attract the attention of Rituxan's developers, Genentech and Biogen Idec."

OK, I know we're all heartily sick of the promising small pharmacos, but I thought I'd bring this one to your attention because the demise of one much-hyped drug can indeed have a positive knock-on effect elsewhere. Furthermore, there doesn't seem to be much medication out there for Lupus.

This company is run by experienced people who have previously worked for some of the majors like GSK, Bristol-Myers Squibb, etc, and in investment banking. Their research results have been positive so far.

I made a good profit on these last year and the sp seems to have turned up again recently. Bought back again this morning. (NB: too small to trade in CFDs)

Notification of Interim Results


http://www.moneyam.com/action/news/showArticle?id=4448448

Starting to recover, strong buying today. Up 8% today

12.5% rise today

up nearly 10%

:-))

Interim Results

INTERIM HIGHLIGHTS



· LupuzorTM, our candidate for the treatment of lupus which has been granted approval by the US Food and Drug Administration to begin Phase III trials under Special Protocol Assessment with Fast Track designation, continues to be the subject of licensing discussions with a number of possible partners



· IPP-204106, ImmuPharma's cancer programme, has begun dosing in a new clinical trial with the next generation of 'polyplexed Nucant'. This 'polyplexed Nucant' formulation has shown an impressive efficacy of about 10 times over the previous Nucant version in pre-clinical cancer models and represents a newly discovered form using the previous Nucant version together with a specific excipient that forms micro/nano structures (see separate announcement released today)



· IPP-204106, final results are available for the Phase I/IIa clinical trial where 6 out of the 14 patients had proven stabilisation with stabilisation lasting more than 6 months in 2 of the 6 patients. No serious drug related adverse events were reported



· Received the New Economy award for Best Medical Research and Development Company Europe 2012



· Strong cash position of £10.1 million



· Basic and diluted loss per share 2.17p and 2.17p respectively (30 June 2011: 2.59p and 2.59p).



http://www.moneyam.com/action/news/showArticle?id=4452077

RNS
RNS Number : 1519N
Immupharma PLC
26 September 2012



FOR IMMEDIATE RELEASE
26 September 2012




ImmuPharma plc



Cancer programme IPP-204106 progresses into further clinical trials



First cancer patients in new trial begin dosing



ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist drug discovery and development company, is pleased to announce that its cancer programme IPP-204106 has begun further clinical trials with the next generation of "polyplexed Nucant".



The first patients have started dosing in this new Phase I/II clinical trial.This "polyplexed Nucant" formulation has shown an impressive efficacy of about 10 times over the previous Nucant version in pre-clinical cancer models and represents a new discovery in that it combines the previous IPP-204106 Nucant version with a specific excipient that forms micro/nano structures. IPP-204106 has a novel mechanism of action aimed at preventing proliferation, inducing apoptosis and also controlling angiogenesis.



ImmuPharma has made promising progress with its anti-cancer nucleolin antagonist ("Nucant") peptide programme. Having received approval from the French regulatory authorities, Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS) it initiated an initial Phase I dose ranging tolerability and safety study in three hospitals in France which is now completed. Patients were suffering from different types of cancer including breast, lung and bladder cancers which had all metastasised. No serious drug related adverse events were reported. 6 out of the 14 patients had a proven stabilization and for 2 out of the 6 the stabilization lasted for more than 6 months.

For this next Phase I/II study based on the next generation "polyplexed Nucant", it is planned to re-evaluate the safety in a preliminary Phase I dose ranging tolerability study with the new formulation (first dose level about to be completed shortly) followed by a Phase II efficacy study designed to treat various cancers in approximately 30 patients to identify appropriate biomarkers. This trial will be conducted in three hospitals in Europe including the prestigious Institute Jules Bordet, an Integrated Multidisciplinary Centre which is the only autonomous hospital in Belgium totally dedicated to cancer. Our further intention is to conduct follow-up studies on patients showing the appropriate biomarkers with glioblastoma (brain tumour), metastatic melanoma, and pancreatic cancer where nucleolin plays a key role.

Recent scientific publications have demonstrated that by interfering with the pathway of nucleolin and other related membrane proteins, a strong growth inhibition of cancer cells as well as a strong induction of apoptosis was observed confirming initial results. In May 2011, IPP-204106 (also referred to as N6L) was chosen to feature on the front cover of 'Cancer Research', a prestigious medical journal of the American Association for Cancer Research. The article was entitled 'A Simple Approach to Cancer Therapy Afforded by Multivalent Pseudopeptides That Target Cell-Surface Nucleoproteins', and was authored by a number of researchers working at or with the CNRS, the research institution with which ImmuPharma is collaborating.



Dr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief Scientific Officer, commented: "The clinical development of our cancer programme continues to be a key priority for ImmuPharma. It is therefore extremely encouraging to see the first patients dosed in this new trial. The improved formulation of the "polyplexed Nucant" is a great achievement for both ImmuPharma and our partner, the CNRS, and further strengthens our position in this field."

Good buying, keeping a close watch on this. Saw a sell rec yesterday due to late news

:-))

On wednesday - peel hunt said sell.

Immupharma (Berlin: 25I.BE - news) falls 4.8 percent as the drug discovery firm posts first-half results in which it says licensing discussions for its Lupus treatment, Lupuzor are continuing, leading Peel Hunt to repeat its "sell" rating on the stock.

ImmuPharma to present Lupuzor data later this month
8:15 am by Ian LyallImmuPharma is currently looking for a partner to take Lupuzor into the final phase of clinical trials.



ImmuPharma (LON:IMM) confirmed this morning that it will present data on its lead drug candidate Lupuzor to the prestigious annual American College of Rheumatology meeting later this month.

The ACR recently confirmed it had accepted the group’s abstract paper on phase IIb data from the Lupuzor trial.

The presentation will be given on November 14 by ImmuPharma’s chief scientific officer Robert Zimmer and Professor Daniel Wallace of the Cedars-Sinai Medical Centre in Los Angeles, a leading authority on Lupus.

Lupuzor was developed to treat the chronic autoimmune disease Lupus and has blockbuster potential.

It has also been given fast-track designation by America’s all-powerful Food & Drug Administration.

The company is currently looking for a partner to take Lupuzor into the final phase of clinical trials.

sp likely to go to sleep until the results of the lupuzor trials become imminent
given the likely high volatility, i have just sold the balance of my trading position at 130 for a modest profit, but shall retain the medium stake in my sipp

All looking good here imo
Can't believe how little posting goes on here. Have been in since 88p days so am happy with current performance. Will hold for the results of the trials..could be big gains to be made but all very speculative. dyor etc but GLA!

IMM
PI's excluded (shafted) yet again!

ImmuPharma raises £10m
Specialist drug discovery and development company ImmuPharma has raised £10m, gross, through a placing of 6,944,445 new ordinary shares at 144p apiece with new and existing investors


explains the weakness of sp over the last few days
that said, the placing was at 144 which is at only a very small discount

IMM has been clattered today by about 18% on the back of the following .....

Tim McCarthy, the Company's Non-executive Chairman (IMM), is currently on the board of Harvard Healthcare Limited ("Harvard"). On 5 March 2018 the Directors of Harvard passed a board resolution following which Harvard will be placed into a Creditors' Voluntary


however, i do not see the direct relevance to IMM
is there something i have missed?

160p to close the gap anybody?

Gap closed intra-day.

All looking good so far imvho. GLA

Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% "responders"**) in the primary analysis on the Full Analysis Set of all 202 patients (including withdrawals who are considered non-responders). However, due to a high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met.

===============

OUCH!
serves me right but fortunately not too many
is there now anything left in this company top sell?
if they're lucky, they may be taken out by a bigger fish